You are here: Industry Insights > SMC

News List

SMC recommends three new medicines for routine use europeanpharmaceuticalreview
May 06, 2019
The Scottish Medicines Consortium has published advice accepting three new medicines for routine use…
Ocrelizumab reccommended for relapsing remitting multiple sclerosis europeanpharmaceuticalreview
April 16, 2019
Ocrelizumab has been recommended by the Scottish Medicines Consortium to treat relapsing remitting multiple sclerosis (RRMS) in adults...
Four new medicines available via NHS Scotland pharmatimes
November 27, 2018
The Scottish Medicines Consortium has cleared funds for use of four new medicines by NHS Scotland, including Sanofi’s biologic Dupixent for dermatitis.
SMC endorses EUSA Pharma’s Qarziba pharmatimes
November 14, 2018
A medicine used to treat a rare cancer that predominantly occurs in very young children is to be routinely funded on the NHS in Scotland.
Four new therapies to be funded by NHS Scotland pharmatimes
October 11, 2018
The Scottish Medicines Consortium has endorsed NHS funding for four therapies, offering new treatment options for acute myeloid leukaemia...
Four new medicines cleared for use on NHS Scotland pharmatimes
August 15, 2018
The Scottish Medicines Consortium has approved funding for four newly licensed medicines, expanding NHS treatments options in Scotland for ovarian cancer, lung cancer, urea cycle disorders and acute hereditary angioedema.
SMC endorses five new therapies for NHS Scotland pharmatimes
April 11, 2018
Scottish cost regulators have approved funding for five new therapies on the NHS, offering new treatment options for a range of conditions.
SMC nod for Novartis’ Kisqali, MSD’s Keytruda pharmatimes
March 14, 2018
The SMC said it was highlighted during the PACE meeting that Kisqali can increase the period of time patients have until their condition progresses and as an oral treatment is easy to administer.
Scotland approves three new meds for NHS use pharmatimes
November 15, 2017
The Scottish Medicines Consortium (SMC) has published new advice accepting three new medicines for use by NHS Scotland, offering patients new treatment options for soft tissue sarcoma, acromegaly and hepatitis C.
SMC approves daratumumab for myeloma patients in Scotland pharmaceufical-technology
October 12, 2017
The Scottish Medicines Consortium (SMC) has approved the use of daratumumab (Darzalex) to treat myeloma patients on National Health Service (NHS) Scotland.

Previous page 1 2 3 4 Next page